Skip to Main Content
It looks like you're using Internet Explorer 11 or older. This website works best with modern browsers such as the latest versions of Chrome, Firefox, Safari, and Edge. If you continue with this browser, you may see unexpected results.

Hadassah Medical Center: Rosenmann Hanna

Last updated June 2021 - Hadassah Medical Center

List of Publications

(1) Appel S, Cohen OS, Chapman J, Gilat S, Rosenmann H, Nitsan Z, et al. Spatial distribution of abnormal EEG activity in Creutzfeldt-Jakob disease. Neurophysiol Clin 2021.

(2) Binyamin O, Nitzan K, Frid K, Ungar Y, Rosenmann H, Gabizon R. Author Correction: Brain targeting of 9c,11t-Conjugated Linoleic Acid, a natural calpain inhibitor, preserves memory and reduces Aβ and P25 accumulation in 5XFAD mice (Scientific Reports, (2019), 9, 1, (18437), 10.1038/s41598-019-54971-9). Sci Rep 2020;10(1).

(3) Nitsan Z, Cohen OS, Chapman J, Kahana E, Korczyn AD, Appel S, et al. Familial Creutzfeldt–Jakob disease homozygous to the E200K mutation: clinical characteristics and disease course. J Neurol 2020;267(8):2455-2458.

(4) Cohen OS, Kahana E, Korczyn AD, Ziv-Baran T, Nitsan Z, Appel S, et al. Pseudo-anticipation in Creutzfeldt–Jakob disease is due to a rhomboid-shaped artifact. Eur J Neurol 2020;27(4):596-602.

(5) Lahiani-Cohen I, Touloumi O, Lagoudaki R, Grigoriadis N, Rosenmann H. Exposure to 3-Nitropropionic Acid Mitochondrial Toxin Induces Tau Pathology in Tangle-Mouse Model and in Wild Type-Mice. Front Cell Dev Biol 2020;7.

(6) Benhamron S, Nitzan K, Valitsky M, Lax N, Karussis D, Kassis I, et al. Cerebrospinal Fluid (CSF) Exchange Therapy with Artificial CSF Enriched with Mesenchymal Stem Cell Secretions Ameliorates Cognitive Deficits and Brain Pathology in Alzheimer's Disease Mice. J Alzheimer's Dis 2020;76(1):369-385.

(7) Binyamin O, Nitzan K, Frid K, Ungar Y, Rosenmann H, Gabizon R. Brain targeting of 9c,11t-Conjugated Linoleic Acid, a natural calpain inhibitor, preserves memory and reduces Aβ and P25 accumulation in 5XFAD mice. Sci Rep 2019;9(1).

(8) Appel S, Cohen OS, Chapman J, Gilat S, Rosenmann H, Nitsan Z, et al. The association of quantitative EEG and MRI in Creutzfeldt-Jakob Disease. Acta Neurol Scand 2019;140(5):366-371.

(9) Cohen OS, Chapman J, Korczyn AD, Nitsan Z, Appel S, Kahana E, et al. Disease duration in E200K familial Creutzfeldt–Jakob disease is correlated with clinical, radiological, and laboratory variables. J Neural Transm 2019;126(5):607-611.

(10) Valitsky M, Benhamron S, Nitzan K, Karussis D, Ella E, Abramsky O, et al. Cerebrospinal fluid (CSF) exchange with artificial csf enriched with mesenchymal stem cell secretions ameliorates experimental autoimmune encephalomyelitis. Int J Mol Sci 2019;20(7).

(11) Nitzan K, Benhamron S, Valitsky M, Kesner EE, Lichtenstein M, Ben-Zvi A, et al. Mitochondrial Transfer Ameliorates Cognitive Deficits, Neuronal Loss, and Gliosis in Alzheimer's Disease Mice. J Alzheimers Dis 2019;72(2):587-604.

(12) Benhamron S, Rozenstein-Tsalkovich L, Nitzan K, Abramsky O, Rosenmann H. Phos-tau peptide immunization of amyloid-tg-mice reduced non-mutant phos-tau pathology, improved cognition and reduced amyloid plaques. Exp Neurol 2018;303:48-58.

(13) Cohen OS, Chapman J, Korczyn AD, Siaw OL, Warman-Alaluf N, Nitsan Z, et al. Clinical radiological correlation in E200K familial Creutzfeldt–Jakob disease. J Neural Transm 2016;123(12):1457-1462.

(14) Cohen OS, Chapman J, Korczyn AD, Siaw OL, Warman-Alaluf N, Nitsan Z, et al. CSF tau correlates with the degree of cortical involvement in E200K familial Creutzfeldt-Jakob disease. Neurosci Lett 2016;634:76-78.

(15) Cohen OS, Kimiagar I, Korczyn AD, Nitsan Z, Appel S, Hoffmann C, et al. Unusual presentations in patients with E200K familial Creutzfeldt-Jakob disease. Eur J Neurol 2016;23(5):871-877.

(16) Cohen OS, Chapman J, Korczyn AD, Warman-Alaluf N, Nitsan Z, Appel S, et al. CSF tau correlates with CJD disease severity and cognitive decline. Acta Neurol Scand 2016;133(2):119-123.

(17) Hellmann MA, Kakhlon O, Landau EH, Sadeh M, Giladi N, Schlesinger I, et al. Frequent misdiagnosis of adult polyglucosan body disease. J Neurol 2015;262(10):2346-2351.

(18) Orhan Akman H, Kakhlon O, Coku J, Peverelli L, Rosenmann H, Rozenstein-Tsalkovich L, et al. Deep intronic GBE1 mutation in manifesting heterozygous patients with adult polyglucosan body disease. JAMA Neurol 2015;72(4):441-445.

(19) Cohen OS, Chapman J, Korczyn AD, Nitsan Z, Appel S, Hoffmann C, et al. Familial Creutzfeldt–Jakob disease with the E200K mutation: longitudinal neuroimaging from asymptomatic to symptomatic CJD. J Neurol 2015;262(3):604-613.

(20) Appel S, Chapman J, Cohen OS, Rosenmann H, Nitsan Z, Blatt I. Seizures in E200K familial and sporadic Creutzfeldt-Jakob disease. Acta Neurol Scand 2015;131(3):152-157.

(21) Cohen OS, Chapman J, Korczyn AD, Warman-Alaluf N, Orlev Y, Givaty G, et al. Characterization of sleep disorders in patients with E200K familial Creutzfeldt–Jakob disease. J Neurol 2015;262(2):443-450.

(22) Jiang T, Chang RC-, Rosenmann H, Yu J-. Advances in Alzheimer's disease: From bench to bedside. BioMed Res Int 2015;2015.

(23) Gotkine M, Rozenstein L, Einstein O, Abramsky O, Argov Z, Rosenmann H. Erratum: Presymptomatic treatment with acetylcholinesterase antisense oligonucleotides prolongs survival in ALS (G93A-SOD1) mice (BioMed Research International). BioMed Res Int 2015;2015.

(24) Mattsson N, Andreasson U, Persson S, Carrillo MC, Collins S, Chalbot S, et al. Erratum: CSF biomarker variability in the Alzheimer's Association quality control program (Alzheimer's and Dementia (2013) 9 (251-261)). Alzheimer's Dementia 2015;11(2):237.

(25) Rosenmann H. Asparagine endopeptidase cleaves tau and promotes neurodegeneration. Nat Med 2014;20(11):1236-1238.

(26) Rozenstein-Tsalkovich L, Grigoriadis N, Lourbopoulos A, Nousiopoulou E, Kassis I, Abramsky O, et al. Repeated immunization of mice with phosphorylated-tau peptides causes neuroinflammation. Exp Neurol 2013;248:451-456.

(27) Boimel M, Grigoriadis N, Lourbopoulos A, Haber E, Abramsky O, Rosenmann H. Corrigendum to "Efficacy and safety of immunization with phosphorylated tau against neurofibrillary tangles in mice" [Exp. Neurol. 224/2 (2010) 472-485]. Exp Neurol 2013;247:8.

(28) Rosenmann H. Immunotherapy for targeting tau pathology in Alzheimer's disease and tauopathies. Curr Alzheimer Res 2013;10(3):217-228.

(29) Mattsson N, Andreasson U, Persson S, Carrillo MC, Collins S, Chalbot S, et al. CSF biomarker variability in the Alzheimer's Association quality control program. Alzheimer's Dementia 2013;9(3):251-261.

(30) Rosenmann H, Meiner Z. [Frontotemporal dementia: clinical features, genetics, pathogenesis and treatment]. Harefuah 2013;152(11):661-"666, 687".

(31) Lee H, Cohen OS, Rosenmann H, Hoffmann C, Kingsley PB, Korczyn AD, et al. Cerebral white matter disruption in Creutzfeldt-Jakob disease. Am J Neuroradiol 2012;33(10):1945-1950.

(32) Rosenmann H, Blum D, Kayed R, Ittner LM. Tau protein: Function and pathology. Int J Alzheimer's Dis 2012.

(33) Mochel F, Schiffmann R, Steenweg ME, Akman HO, Wallace M, Sedel F, et al. Adult polyglucosan body disease: Natural history and key magnetic resonance imaging findings. Ann Neurol 2012;72(3):433-441.

(34) Rosenmann H. CSF biomarkers for amyloid and tau pathology in Alzheimer's disease. J Mol Neurosci 2012;47(1):1-14.

(35) Cohen OS, Prohovnik I, Korczyn AD, Inzelberg R, Nitsan Z, Appel S, et al. Characterization of movement disorders in patients with familial creutzfeldt-jakob disease carrying the E200K mutation. Isr Med Assoc J 2012;14(3):162-165.

(36) Meiner Z, Rosenmann H. [Biological markers in the diagnosis of dementia and Alzheimer's disease]. Harefuah 2012;151(5):289-"293, 318".

(37) Cohen OS, Prohovnik I, Korczyn AD, Ephraty L, Nitsan Z, Tsabari R, et al. The Creutzfeldt-Jakob disease (CJD) neurological status scale: A new tool for evaluation of disease severity and progression. Acta Neurol Scand 2011;124(6):368-374.

(38) Lahiani-Cohen I, Lourbopoulos A, Haber E, Rozenstein-Tsalkovich L, Abramsky O, Grigoriadis N, et al. Moderate environmental enrichment mitigates tauopathy in a neurofibrillary tangle mouse model. J Neuropathol Exp Neurol 2011;70(7):610-621.

(39) Ginsburg I, Rozenstein-Tsalkovich L, Koren E, Rosenmann H. The herbal preparation padma® 28 protects against neurotoxicity in PC12 cells. Phytother Res 2011;25(5):740-743.

(40) Meiner Z, Kahana E, Baitcher F, Korczyn AD, Chapman J, Cohen OS, et al. Tau and 14-3-3 of genetic and sporadic Creutzfeldt-Jakob disease patients in Israel. J Neurol 2011;258(2):255-262.

(41) Cohen OS, Chapman J, Lee H, Nitsan Z, Appel S, Hoffman C, et al. Pruritus in familial Creutzfeldt-Jakob disease: A common symptom associated with central nervous system pathology. J Neurol 2011;258(1):89-95.

(42) Boimel M, Grigoriadis N, Lourbopoulos A, Haber E, Abramsky O, Rosenmann H. Efficacy and safety of immunization with phosphorylated tau against neurofibrillary tangles in mice. Exp Neurol 2010;224(2):472-485.

(43) Appel SA, Chapman J, Kahana E, Rosenmann H, Prohovnik I, Pras E, et al. Rapidly progressive Creutzfeldt-Jakob disease in patients with Familial Mediterranean Fever. Eur J Neurol 2010;17(6):861-865.

(44) Shiryaev N, Jouroukhin Y, Giladi E, Polyzoidou E, Grigoriadis NC, Rosenmann H, et al. NAP protects memory, increases soluble tau and reduces tau hyperphosphorylation in a tauopathy model. Neurobiol Dis 2009;34(2):381-388.

(45) Boimel M, Grigoriadis N, Lourbopoulos A, Touloumi O, Rosenmann D, Abramsky O, et al. Statins reduce the neurofibrillary tangle burden in a mouse model of tauopathy. J Neuropathol Exp Neurol 2009;68(3):314-325.

(46) Dresner-Pollak R, Kinnar T, Friedlander Y, Sharon N, Rosenmann H, Pollak A. Estrogen receptor beta gene variant is associated with vascular dementia in elderly women. Genet Test Mol Biomarkers 2009;13(3):339-342.

(47) Lee H, Rosenmann H, Chapman J, Kingsley PB, Hoffmann C, Cohen OS, et al. Thalamo-striatal diffusion reductions precede disease onset in prion mutation carriers. Brain 2009;132(10):2680-2687.

(48) Rosenmann H, Grigoriadis N, Eldar-Levy H, Avital A, Rozenstein L, Touloumi O, et al. A novel transgenic mouse expressing double mutant tau driven by its natural promoter exhibits tauopathy characteristics. Exp Neurol 2008;212(1):71-84.

(49) Rosenmann H, Meiner Z, Geylis V, Abramsky O, Steinitz M. Detection of circulating antibodies against tau protein in its unphosphorylated and in its neurofibrillary tangles-related phosphorylated state in Alzheimer's disease and healthy subjects. Neurosci Lett 2006;410(2):90-93.

(50) Rosenmann H, Grigoriadis N, Karussis D, Boimel M, Touloumi O, Ovadia H, et al. Tauopathy-like abnormalities and neurologic deficits in mice immunized with neuronal tau protein. Arch Neurol 2006;63(10):1459-1467.

(51) Meiner V, Weinberg N, Safran A, Israela L, Sagi M, Rosenmann H, et al. Preimplantation exclusion of embryos at risk for prion diseases. Neurology 2006;66(4):607-608.

(52) Lossos A, Khoury M, Rizzo WB, Gomori JM, Banin E, Zlotogorski A, et al. Phenotypic variability among adult siblings with Sjögren-Larsson syndrome. Arch Neurol 2006;63(2):278-280.

(53) Lossos A, Soffer D, Steiner-Birmanns B, Hassin-Baer S, Sadeh M, Sagi M, et al. Extended phenotype in the transthyretin Tyr77 familial amyloid polyneuropathy. Eur Neurol 2005;53(2):55-59.

(54) Rosenmann H, Meiner Z, Kahana E, Aladjem Z, Friedman G, Ben-Yehuda A, et al. An association study of a polymorphism in the heparan sulfate proteoglycan gene (perlecan, HSPG2) and Alzheimer's disease. Am J Med Genet Neuropsychiatr Genet 2004;128 B(1):123-125.

(55) Rosenmann H, Meiner Z, Dresner-Pollak R, Kahana E, Aladjem Z, Grenader T, et al. Lack of association of interleukin-1beta polymorphism with Alzheimer's disease in the Jewish population. Neurosci Lett 2004;363(2):131-133.

(56) Rosenmann H, Meiner Z, Kahana E, Aladjem Z, Friedman G, Ben-Yehuda A, et al. The fas promoter polymorphism at position -670 is not associated with late-onset sporadic Alzheimer's disease. Dementia Geriatr Cogn Disord 2004;17(3):143-146.

(57) Hijazi N, Shaked Y, Rosenmann H, Ben-Hur T, Gabizon R. Copper binding to PrPC may inhibit prion disease propagation. Brain Res 2003;993(1-2):192-200.

(58) Lossos A, Reches A, Gal A, Newman JP, Soffer D, Gomori JM, et al. Frontotemporal dementia and parkinsonism with the P301S tau gene mutation in a Jewish family. J Neurol 2003;250(6):733-740.

(59) Rosenmann H, Meiner Z, Kahana E, Aladjem Z, Friedman G, Ben-Yehuda A, et al. An association study of the codon 72 polymorphism in the pro-apoptotic gene p53 and Alzheimer's disease. Neurosci Lett 2003;340(1):29-32.

(60) Rosenmann H, Meiner Z, Kahana E, Aladjem Z, Friedman G, Ben-Yehuda A, et al. A polymorphism in the complement component C1r is not associated with sporadic Alzheimer's disease. Neurosci Lett 2003;336(2):101-104.

(61) Shaked GM, Engelstein R, Avraham I, Rosenmann H, Gabizon R. Valproic acid treatment results in increased accumulation of prion proteins. Ann Neurol 2002;52(4):416-420.

(62) Shaked Y, Rosenmann H, Hijazi N, Halimi M, Gabizon R. Copper binding to the PrP isoforms: A putative marker of their conformation and function. J Virol 2001;75(17):7872-7874.

(63) Rosenmann H, Talmor G, Halimi M, Yanai A, Gabizon R, Meiner Z. Prion protein with an E200K mutation displays properties similar to those of the cellular isoform PrPC. J Neurochem 2001;76(6):1654-1662.

(64) McNally EM, Ly T, Rosenmann H, Rosenbaum SM, Jiang W, Anderson LVB, et al. Splicing mutation in dysferlin produces limb-girdle muscular dystrophy with inflammation. Am J Med Genet 2000;91(4):305-312.

(65) Simon ES, Kahana E, Chapman J, Treves TA, Gabizon R, Rosenmann H, et al. Creutzfeldt-Jakob disease profile in patients homozygous for the PRNP E200k mutation. Ann Neurol 2000;47(2):257-260.

(66) Argov Z, Sadeh M, Mazor K, Soffer D, Kahana E, Eisenberg I, et al. Muscular dystrophy due to dysferlin deficiency in Libyan Jews. Clinical and genetic features. Brain 2000;123(6):1229-1237.

(67) Shaked Y, Rosenmann H, Talmor G, Gabizon R. A C-terminal-truncated PrP isoform is present in mature sperm. J Biol Chem 1999;274(45):32153-32158.

(68) Rosenmann H, Kahana E, Korczyn AD, Kahana I, Chapman J, Gabizon R. Preliminary evidence for anticipation in genetic E200K Creutzfeldt-Jakob disease. Neurology 1999;53(6):1328-1329.

(69) Rosenmann H, Vardi J, Finkelstein Y, Chapman J, Gabizon R. Identification in Israel of 2 Jewish Creutzfeldt-Jakob disease patients with a 178 mutation at their PrP gene. Acta Neurol Scand 1998;97(3):184-187.

(70) Rosenmann H, Halimi M, Kahana I, Biran I, Gabizon R. Differential allelic expression of PrP mRNA in carriers of the E200K mutation. Neurology 1997;49(3):851-856.

(71) Rosenmann H, Meiner Z, Kahana E, Halimi M, Lenetsky E, Abramsky O, et al. Detection of 14-3-3 protein in the CSF of genetic Creutzfeldt Jakob disease. Neurology 1997;49(2):593-595.

(72) Ovadia H, Rosenmann H, Shezen E, Halimi M, Ofran I, Gabizon R. Effect of scrapie infection on the activity of neuronal nitric-oxide synthase in brain and neuroblastoma cells. J Biol Chem 1996;271(28):16856-16861.

(73) Spudich S, Mastrianni JA, Wrensch M, Gabizon R, Meiner Z, Kahana I, et al. Complete penetrance of Cruetzfeldt-Jakob disease in Libyan Jews carrying the E200K mutation in the prion protein gene. Mol Med 1995;1(6):607-613.

(74) Gabizon R, Rosenmann H, Meiner Z, Kahana I, Kahana E, Shugart Y, et al. Mutation and polymorphism of the prion protein gene in Libyan Jews with Creutzfeldt-Jakob disease (CJD). Am J Hum Genet 1993;53(4):828-835.